Long term 24 hour intestinal administration of levodopa/carbidopa

A levodopa, 24-hour technology for neurological diseases, organic active ingredients, pharmaceutical formulations, etc.

Active Publication Date: 2010-01-27
ABBVIE PHARMA GMBH
View PDF1 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Opened boxes should not be used again

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Long term 24 hour intestinal administration of levodopa/carbidopa
  • Long term 24 hour intestinal administration of levodopa/carbidopa
  • Long term 24 hour intestinal administration of levodopa/carbidopa

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] Most patients with PD suffer from sleep disorders. In advanced PD, dopaminergic drugs are sometimes used frequently at night to improve sleep. Because of concerns about tolerability and psychiatric side effects, levodopa was administered for 24 consecutive hours only in a very small number of patients and in a short period of time. Researched the 24-hour duodenal administration of levodopa / carbidopa ( ) Of 5 cases, lasting until 37 months.

[0052] method

[0053] The hospital chart was reviewed retrospectively in 5 PD patients who received a 4:1 weight ratio of levodopa / carbidopa in the gel for 24 hours ( ) Duodenal administration by enteral administration. The formulation is described in US Patent No. 5,635,213, which is incorporated into this application by reference. Record dosage, efficacy, sleep patterns and side effects.

[0054] For their health, the patients were treated with this regimen. Therefore, no prospective research protocol was used. In one case, the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
Login to view more

Abstract

A method of treating Parkinson's Disease comprising intestinally administering to a patient in need thereof a pharmaceutically effective amount of a composition comprising levodopa and optionally carbidopa continuously over a period of greater than 16 hours.

Description

[0001] Related application [0001] This application claims the priority of the U.S. provisional application serial number 60 / 809,889 filed on May 31, 2006, which is fully incorporated into this application by reference to the extent permitted by law. Technical field [0002] The present invention relates to the use of a pharmaceutical composition containing levodopa and with or without carbidopa for the treatment of Parkinson's disease ("PD"). Background technique [0003] Parkinson's disease is a progressive disease; the disease continues to worsen. For example, as Parkinson's disease becomes more advanced ("advanced PD"), facial movements, blinking, and spontaneous smiles and expressions all become more difficult, and people have increased difficulty in independent activities. [0004] Intestinal, for example duodenal and / or jejunal administration (through external contact points) a pharmaceutical composition comprising levodopa / carbidopa, such as under the trade name Composition...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K31/192A61K31/198A61K45/06A61P25/16
CPCA61K9/0024A61K31/198A61K9/06A61K31/192A61K9/10A61K31/195A61P25/16A61K2300/00
Inventor D·尼霍姆S·阿斯伯格R·博尔苏伊M·图奇克-塞特勒
Owner ABBVIE PHARMA GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap